Cargando…

YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC

The Yes-associated protein (YAP) is a transcriptional co-activator upregulating genes that promote cell growth and inhibit apoptosis. The main dysregulation of the Hippo pathway in tumors is due to YAP overexpression, promoting epithelial to mesenchymal transition, cell transformation, and increased...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghiso, Elena, Migliore, Cristina, Ciciriello, Vito, Morando, Elena, Petrelli, Annalisa, Corso, Simona, De Luca, Emmanuele, Gatti, Gaia, Volante, Marco, Giordano, Silvia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2017
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683041/ https://www.ncbi.nlm.nih.gov/pubmed/29136529 http://dx.doi.org/10.1016/j.neo.2017.10.003

Ejemplares similares

Targeting AXL in NSCLC
por: Zaman, Aubhishek, et al.
Publicado: (2021)

miR‐205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling
por: Migliore, Cristina, et al.
Publicado: (2018)

Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway
por: Sun, Qi, et al.
Publicado: (2022)

NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors
por: McGowan, Marc, et al.
Publicado: (2017)

AXL receptor tyrosine kinase as a therapeutic target in NSCLC
por: Okimoto, Ross A, et al.
Publicado: (2015)

Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition
por: Corso, Simona, et al.
Publicado: (2010)

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
por: Chaib, Imane, et al.
Publicado: (2017)

Overexpression of INSM1, NOTCH1, NEUROD1, and YAP1 genes is associated with adverse clinical outcome in pediatric neuroblastoma
por: Metovic, Jasna, et al.
Publicado: (2022)

Repression of YAP by NCTD disrupts NSCLC progression
por: Guo, Jiwei, et al.
Publicado: (2016)

Unexpected responses to EGFR inhibition in NSCLC
por: Stella, Giulia M., et al.
Publicado: (2015)

Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma
por: Lamhamedi-Cherradi, Salah-Eddine, et al.
Publicado: (2021)

TGFβ promotes YAP‐dependent AXL induction in mesenchymal‐type lung cancer cells
por: Choi, Jeong‐Yun, et al.
Publicado: (2020)

AXL/epidermal growth factor receptor (EGFR) complexes in breast cancer - culprits for resistance to EGFR inhibitors?
por: Heideman, Marinus R, et al.
Publicado: (2013)

The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC
por: Jin, Dan, et al.
Publicado: (2018)

Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer
por: Zhang, Zhenfeng, et al.
Publicado: (2012)

Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
por: Yan, Dan, et al.
Publicado: (2021)

Tumor Microenvironmental Cytokines Drive NSCLC Cell Aggressiveness and Drug-Resistance via YAP-Mediated Autophagy
por: Matarrese, Paola, et al.
Publicado: (2023)

Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells
por: Dufies, Maeva, et al.
Publicado: (2011)

Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells
por: Vouri, M, et al.
Publicado: (2016)

AXL cooperates with EGFR to mediate neutrophil elastase-induced migration of prostate cancer cells
por: Xiao, Zhiguang, et al.
Publicado: (2021)

Giving AXL the axe: targeting AXL in human malignancy
por: Gay, Carl M, et al.
Publicado: (2017)

The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy
por: Friedlaender, Alex, et al.
Publicado: (2021)

YAP regulates PD-L1 expression in human NSCLC cells
por: Miao, Jinbai, et al.
Publicado: (2017)

Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow
por: Yumoto, Kenji, et al.
Publicado: (2016)

Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours
por: Green, J, et al.
Publicado: (2006)

ARL2 overexpression inhibits glioma proliferation and tumorigenicity via down-regulating AXL
por: Wang, Yulin, et al.
Publicado: (2018)

Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors
por: Nakamura, Ryota, et al.
Publicado: (2023)

The crosstalk between AXL and YAP promotes tumor progression through STAT3 activation in head and neck squamous cell carcinoma
por: Li, Jiayi, et al.
Publicado: (2020)

Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer
por: Truong, Danh D., et al.
Publicado: (2022)

Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
por: Terp, Mikkel G., et al.
Publicado: (2021)

Sulforaphane attenuates EGFR signaling in NSCLC cells
por: Chen, Chi-Yuan, et al.
Publicado: (2015)

EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
por: Sattler, Martin, et al.
Publicado: (2008)

Targeting AXL and RAGE to prevent geminin overexpression-induced triple-negative breast cancer metastasis
por: Ryan, Daniel, et al.
Publicado: (2019)

AXL Overexpression in Tumor-Derived Endothelial Cells Promotes Vessel Metastasis in Patients With Hepatocellular Carcinoma
por: Chai, Zong-Tao, et al.
Publicado: (2021)

AXL, along with PROS1, is overexpressed in papillary thyroid carcinoma and regulates its biological behaviour
por: Wei, Mingze, et al.
Publicado: (2022)

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
por: Russo, Alessandro, et al.
Publicado: (2015)

AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells
por: Choi, Yun Jung, et al.
Publicado: (2015)

Primary resistance to EGFR inhibition in glioblastoma is mediated by a TNF-JNK-Axl-ERK signaling axis
por: Guo, Gao, et al.
Publicado: (2017)

Chemotherapy confers a conserved secondary tolerance to EGFR inhibition via AXL-mediated signaling bypass
por: Aldonza, Mark Borris D., et al.
Publicado: (2021)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f18bl4opea14m1ov1j6lbhv3f2